Vorinostat Completed Phase 1 Trials for Childhood Low-grade Cerebral Astrocytoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Childhood Grade I Meningioma / Childhood Central Nervous System Yolk Sac Tumor / Recurrent Childhood Medulloblastoma / Childhood Central Nervous System Choriocarcinoma / Childhood Ependymoblastoma / Childhood Low-grade Cerebellar Astrocytoma / Recurrent Childhood Spinal Cord Neoplasm / Childhood Craniopharyngioma / Childhood Grade III Meningioma / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Childhood Atypical Teratoid/Rhabdoid Tumor / Childhood Mixed Glioma / Recurrent Childhood Cerebellar Astrocytoma / Childhood Infratentorial Ependymoma / Recurrent Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Mixed Germ Cell Tumor / Recurrent Childhood Cerebral Astrocytoma / Childhood Central Nervous System Germinoma / Recurrent Childhood Brain Stem Glioma / Childhood Choroid Plexus Tumor / Childhood Medulloepithelioma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Childhood High-grade Cerebral Astrocytoma / Childhood Oligodendroglioma / Recurrent Childhood Ependymoma / Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Teratoma / Extra-Adrenal Paraganglioma / Recurrent Childhood Pineoblastoma / Childhood Grade II Meningioma / Childhood Supratentorial Ependymoma / Childhood High-grade Cerebellar Astrocytoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01076530Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors